We are live on ! Find out more
SCM

Squadron Capital Management Portfolio holdings

AUM $322M
This Fund
S&P 500
This Quarter Est. Return
+34.37%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$322M
AUM Growth
+$49.3M
Cap. Flow
+$2.89M
Cap. Flow %
0.9%
Top 10 Hldgs %
66.2%
Holding
60
New
23
Increased
11
Reduced
7
Closed
17

Top Buys

Rank Stock Value
1
CCCC icon
C4 Therapeutics
CCCC
+$16.9M
2
IVA
Inventiva
IVA
+$9.13M
3
ELVN icon
Enliven Therapeutics
ELVN
+$6.79M
4
FBRX icon
Forte Biosciences
FBRX
+$5.34M
5
ADAG
Adagene
ADAG
+$4.7M

Top Sells

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$19.8M
2
ABVX
Abivax
ABVX
+$14.5M
3
NKTR icon
Nektar Therapeutics
NKTR
+$8.99M
4
RLMD icon
Relmada Therapeutics
RLMD
+$7.86M
5
ANL
Adlai Nortye Group ADS
ANL
+$6.09M

Sector Composition

Rank Sector Weight
1 Healthcare 90.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLGL icon
26
Sol-Gel Technologies
SLGL
$253M
$3.86M 1.2%
52,000
+21,000
+68% +$1.54M
BIOA
27
BioAge Labs
BIOA
$431M
$3.8M 1.18%
+155,000
New +$2.8M
SCYX icon
28
SCYNEXIS
SCYX
$52.3M
$3.08M 0.96%
756,884
-194,203
-20% -$1.21M
PRQR icon
29
ProQR Therapeutics
PRQR
$343M
$2.81M 0.87%
+1,511,496
New +$2.49M
IRON icon
30
CALL
Disc Medicine
IRON
$3.11B
$2.19M 0.68%
+30,000
New +$2.06M
RZLT icon
31
Rezolute
RZLT
$482M
$2.1M 0.65%
+403,410
New +$1.5M
LPCN icon
32
Lipocine
LPCN
$17M
$2.07M 0.64%
810,000
+360,000
+80% +$866K
ZNTL icon
33
CALL
Zentalis Pharmaceuticals
ZNTL
$356M
$2.07M 0.64%
426,000
+26,000
+7% +$104K
CCCC icon
34
CALL
C4 Therapeutics
CCCC
$504M
$1.87M 0.58%
+400,000
New +$1.37M
RARE icon
35
CALL
Ultragenyx Pharmaceutical
RARE
$2.54B
$1.84M 0.57%
+55,000
New +$1.37M
CUE icon
36
Cue Biopharma
CUE
$168M
$1.58M 0.49%
+50,000
New +$1.13M
CALC icon
37
CalciMedica
CALC
$17.1M
$1.28M 0.4%
+1,244,864
New +$882K
QNCX icon
38
Quince Therapeutics
QNCX
$34.1M
$734K 0.23%
+40,375
New +$928K
NVCT icon
39
CALL
Nuvectis Pharma
NVCT
$779M
$712K 0.22%
+38,700
New +$433K
KTTA icon
40
Pasithea Therapeutics
KTTA
$16.9M
$515K 0.16%
1,000,000
-1,100,000
-52% -$757K
INM icon
41
InMed Pharmaceuticals
INM
$7.64M
$504K 0.16%
+325,000
New +$359K
NMRA icon
42
Neumora Therapeutics
NMRA
$287M
$170K 0.05%
+100,000
New +$190K
NXTC icon
43
NextCure
NXTC
$27M
$103K 0.03%
64,464
-200,536
-76% -$1.48M
ABVX
44
Abivax
ABVX
$10.1B
– –
-130,000
Closed -$14.5M
ALXO icon
45
ALX Oncology
ALXO
$275M
– –
-1,460,000
Closed -$2.93M
CNTX icon
46
Context Therapeutics
CNTX
$42.8M
– –
-1,100,000
Closed -$2.88M
GHRS icon
47
GH Research
GHRS
$1.93B
– –
-325,000
Closed -$4.57M
HOWL icon
48
Werewolf Therapeutics
HOWL
$42.9M
– –
-563,535
Closed -$469K
IDYA icon
49
CALL
IDEAYA Biosciences
IDYA
$3.86B
– –
-104,300
Closed -$3.48M
IDYA icon
50
PUT
IDEAYA Biosciences
IDYA
$3.86B
– –
-120,000
Closed -$4M
1
2
3

Similar funds

SST
S Squared Technology New York $322M AUM 92.75% 1-Year Est. Return
CW
Curio Wealth Annapolis, Maryland $322M AUM 16.26% 1-Year Est. Return
WW
Westshore Wealth Newport Beach, California $322M AUM 24.46% 1-Year Est. Return
NAG
Northstar Advisory Group Northfield, New Jersey $322M AUM 36.79% 1-Year Est. Return
JGIA
Jackson Grant Investment Advisers Stamford, Connecticut $322M AUM 20.03% 1-Year Est. Return
EI
EnCap Investments Houston, Texas $322M AUM
KF
Ketron Financial Novato, California $322M AUM
QFPS
Quantum Financial Planning Services Spokane, Washington $323M AUM 14.02% 1-Year Est. Return

Squadron Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Squadron Capital Management held 60 positions worth $322M, up 18% from $273M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Squadron Capital Management's Q2 2026 filing shows 23 new, 11 increased, 7 reduced and 17 closed positions. Its largest new stake was Enliven Therapeutics: 160,000 shares worth $8.12M. The largest sale was KalVista Pharmaceuticals, an estimated $19.8M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier.

  • Squadron Capital Management's largest Q2 2026 buy was Enliven Therapeutics: 160,000 shares worth $8.12M.
  • Squadron Capital Management added most to C4 Therapeutics in Q2 2026, an estimated $16.9M increase.
  • Squadron Capital Management's biggest Q2 2026 reduction was Relmada Therapeutics, cutting an estimated $7.86M.
  • Squadron Capital Management fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $19.8M.
  • Squadron Capital Management's ten largest holdings make up 66% of its $322M portfolio in Q2 2026.
  • Squadron Capital Management opened 23 new positions and closed 17 in Q2 2026.
  • Squadron Capital Management's portfolio value rose 18% quarter-over-quarter to $322M.

Based on Squadron Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.